Indian-origin CEO strikes 'significant' UK deal to combat cancer, dementia
Gordon Sanghera, CEO of Oxford Nanopore Technologies, said the development of a world-first “epigenetic map” of the human genome could lead to breakthroughs in new diagnoses and treatments.
